ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results
NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced its financial results for the third quarter of 2024, alongside significant progress in its lead program for firmonertinib, a …
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results Read More